KHB(SZ:002022) 2 1 Shi Ji Jing Ji Bao Dao·2026-01-30 09:49Core Viewpoint - The company, Kehua Bio, forecasts a significant net loss for the year 2025, estimating a loss of between 5.80 billion to 7.40 billion yuan for net profit attributable to shareholders, and a loss of 5.90 billion to 7.50 billion yuan for net profit after deducting non-recurring gains and losses. This reflects the challenges faced in the IVD industry due to intensified competition and adverse policy impacts [1]. Summary by Relevant Sections Financial Performance - The company anticipates a net loss of 5.80 billion to 7.40 billion yuan for 2025, with a net loss of 5.90 billion to 7.50 billion yuan after excluding non-recurring items [1]. Factors Affecting Performance - Major factors impacting performance include: 1. Asset impairment provisions significantly affecting profits, as the company conducts comprehensive assessments and plans to recognize impairment losses based on industry trends and operational realities [1]. 2. Increased market competition and adverse industry policies leading to a decline in both volume and price, resulting in reduced revenue and gross margin [1]. 3. The company is committed to its strategic positioning of "comprehensive yet precise" and "integrated innovation," focusing on national health needs while implementing various measures for stable development [1]. Strategic Initiatives - The company plans to: 1. Strengthen research and sales collaboration to uncover new growth drivers, maintaining R&D investment and enhancing its sales and service network domestically and internationally [1]. 2. Deepen lean management and promote digital transformation to optimize resource allocation and improve operational efficiency, thereby laying a solid foundation for high-quality development [1].